Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
GT Biopharma, Inc. is a clinical-stage biopharmaceutical company developing immuno-oncology therapies using proprietary Tri-specific and Tetra-specific Killer Engager platforms. Its products harness natural killer (NK) cells to target various cancers, including hematologic malignancies and solid tumors. The company focuses on innovative, scalable immunotherapies with potential for monotherapy or combination use, relying on strategic partnerships, intellectual property, and third-party manufacturing.
This description was generated via AI from an annual report. Updated about 1 year ago.